Long‐lasting response to third‐line crizotinib treatment in a patient with non‐small cell lung cancer with brain metastases and poor performance status

Identification of the anaplastic lymphoma kinase (ALK) gene has refined the classification of non‐small cell lung cancer (NSCLC) and promoted research on molecularly targeted drugs such as crizotinib, an ALK inhibitor with good efficacy, in ALK‐rearranged NSCLC. At present, few studies have reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, De‐lan, Chen, Xin‐ru, Ma, Shu‐xiang, Chen, Li‐kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193012/
https://www.ncbi.nlm.nih.gov/pubmed/27766783
http://dx.doi.org/10.1111/1759-7714.12383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193012/
https://www.ncbi.nlm.nih.gov/pubmed/27766783
http://dx.doi.org/10.1111/1759-7714.12383

Ejemplares similares